Apexigen, Inc. Common Stock
APGN
APGN was delisted on the 22nd of August, 2023.
31 hedge funds and large institutions have $25.3M invested in Apexigen, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
14% more capital invested
Capital invested by funds: $22.2M → $25.3M (+$3.06M)
3% more funds holding
Funds holding: 30 → 31 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
+$1.46M |
| 2 |
D.E. Shaw & Co
New York
|
+$618K |
| 3 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$379K |
| 4 |
KC
Kepos Capital
New York
|
+$360K |
| 5 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$192K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
-$374K |
| 2 |
HI
Harbour Investments
Madison,
Wisconsin
|
-$110K |
| 3 |
GCIA
Gabelli & Co Investment Advisers
Rye,
New York
|
-$110K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$55K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$34K |
APGN Hedge Fund Activity: Q3 2021 in Review
31 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Apexigen, Inc. Common Stock (APGN) for Q3 2021, worth a combined $25.3M — up 14% from $22.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new APGN positions and 3 closed out — a net gain of 1 holder — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Basso Capital Management, adding an estimated $1.46M. The largest seller was Bulldog Investors, exiting entirely with an estimated $374K sold.
- 31 institutional investors held Apexigen, Inc. Common Stock (APGN) as of Q3 2021, up from 30 in Q2 2021.
- Funds reported $25.3M of Apexigen, Inc. Common Stock stock for Q3 2021, up 14% quarter-over-quarter.
- 4 funds opened new Apexigen, Inc. Common Stock positions in Q3 2021 and 3 closed out, a net change of +1 holder.
- The largest Apexigen, Inc. Common Stock buyer in Q3 2021 was Basso Capital Management, an estimated $1.46M added.
- The largest Apexigen, Inc. Common Stock seller in Q3 2021 was Bulldog Investors, an estimated $374K sold.
Based on aggregated 13F filings for Q3 2021.